\babel@toc {english}{}\relax 
\contentsline {part}{I\hspace {1em}Notes}{8}{part.1}%
\contentsline {chapter}{\numberline {1}Introduction}{9}{chapter.1}%
\contentsline {section}{\numberline {1.1}Genetics and genomics}{9}{section.1.1}%
\contentsline {subsection}{\numberline {1.1.1}Genetics}{9}{subsection.1.1.1}%
\contentsline {subsection}{\numberline {1.1.2}Genomics}{9}{subsection.1.1.2}%
\contentsline {subsection}{\numberline {1.1.3}Differences between genetics and genomics}{9}{subsection.1.1.3}%
\contentsline {subsection}{\numberline {1.1.4}The role of computational biology}{10}{subsection.1.1.4}%
\contentsline {section}{\numberline {1.2}Basis of human genomics}{10}{section.1.2}%
\contentsline {subsection}{\numberline {1.2.1}Single nucleotide polymorphisms}{10}{subsection.1.2.1}%
\contentsline {subsection}{\numberline {1.2.2}Copy number variants}{10}{subsection.1.2.2}%
\contentsline {subsection}{\numberline {1.2.3}Inherited variants}{10}{subsection.1.2.3}%
\contentsline {subsubsection}{\numberline {1.2.3.1}Penetrance}{11}{subsubsection.1.2.3.1}%
\contentsline {subsubsection}{\numberline {1.2.3.2}Allele frequency}{11}{subsubsection.1.2.3.2}%
\contentsline {subsubsection}{\numberline {1.2.3.3}Differences in Genetic Make-Up, an example}{11}{subsubsection.1.2.3.3}%
\contentsline {subsection}{\numberline {1.2.4}Somatic Variants}{12}{subsection.1.2.4}%
\contentsline {subsubsection}{\numberline {1.2.4.1}Classification}{12}{subsubsection.1.2.4.1}%
\contentsline {subsubsection}{\numberline {1.2.4.2}Types of acquired DNA aberrations}{12}{subsubsection.1.2.4.2}%
\contentsline {paragraph}{\numberline {1.2.4.2.1}Translocation}{12}{paragraph.1.2.4.2.1}%
\contentsline {paragraph}{\numberline {1.2.4.2.2}Inversion}{12}{paragraph.1.2.4.2.2}%
\contentsline {paragraph}{\numberline {1.2.4.2.3}Copy number changes}{13}{paragraph.1.2.4.2.3}%
\contentsline {paragraph}{\numberline {1.2.4.2.4}Chromoplexy}{13}{paragraph.1.2.4.2.4}%
\contentsline {section}{\numberline {1.3}Experimental techniques to detect variants/aberrations}{13}{section.1.3}%
\contentsline {subsection}{\numberline {1.3.1}Karyotyping}{13}{subsection.1.3.1}%
\contentsline {subsection}{\numberline {1.3.2}Sequence capture for cancer genomics}{13}{subsection.1.3.2}%
\contentsline {subsubsection}{\numberline {1.3.2.1}Reference}{13}{subsubsection.1.3.2.1}%
\contentsline {subsubsection}{\numberline {1.3.2.2}Deepness}{14}{subsubsection.1.3.2.2}%
\contentsline {subsubsection}{\numberline {1.3.2.3}Single End (SE) and Paired End (PE) reads}{14}{subsubsection.1.3.2.3}%
\contentsline {paragraph}{\numberline {1.3.2.3.1}Single end sequencing}{14}{paragraph.1.3.2.3.1}%
\contentsline {paragraph}{\numberline {1.3.2.3.2}Paired end sequencing}{14}{paragraph.1.3.2.3.2}%
\contentsline {paragraph}{\numberline {1.3.2.3.3}Ability of paired end sequencing to detect genomic aberrations}{14}{paragraph.1.3.2.3.3}%
\contentsline {chapter}{\numberline {2}Coverage}{15}{chapter.2}%
\contentsline {section}{\numberline {2.1}Computing coverage}{15}{section.2.1}%
\contentsline {subsection}{\numberline {2.1.1}Local coverage}{15}{subsection.2.1.1}%
\contentsline {subsection}{\numberline {2.1.2}Allelic fraction}{15}{subsection.2.1.2}%
\contentsline {subsection}{\numberline {2.1.3}NGS global coverage}{15}{subsection.2.1.3}%
\contentsline {section}{\numberline {2.2}Mapping in NGS}{15}{section.2.2}%
\contentsline {subsection}{\numberline {2.2.1}Sequence coverage}{16}{subsection.2.2.1}%
\contentsline {subsection}{\numberline {2.2.2}Physical coverage}{16}{subsection.2.2.2}%
\contentsline {section}{\numberline {2.3}Tuning coverage}{16}{section.2.3}%
\contentsline {subsection}{\numberline {2.3.1}SNP detection}{16}{subsection.2.3.1}%
\contentsline {subsection}{\numberline {2.3.2}Subclonal events}{16}{subsection.2.3.2}%
\contentsline {subsection}{\numberline {2.3.3}Amplicon-based approaches}{17}{subsection.2.3.3}%
\contentsline {subsubsection}{\numberline {2.3.3.1}Heterozygous deletion of PTEN}{17}{subsubsection.2.3.3.1}%
\contentsline {subsubsection}{\numberline {2.3.3.2}Homozygous deletion of PTEN}{17}{subsubsection.2.3.3.2}%
\contentsline {subsubsection}{\numberline {2.3.3.3}Amplification of AR}{17}{subsubsection.2.3.3.3}%
\contentsline {subsection}{\numberline {2.3.4}NGS-based approaches}{18}{subsection.2.3.4}%
\contentsline {subsubsection}{\numberline {2.3.4.1}Advantages over amplicon-based approaches}{18}{subsubsection.2.3.4.1}%
\contentsline {subsubsection}{\numberline {2.3.4.2}Problems of NGS-based approaches}{18}{subsubsection.2.3.4.2}%
\contentsline {section}{\numberline {2.4}Databases for NGS analysis}{18}{section.2.4}%
\contentsline {subsection}{\numberline {2.4.1}Genome reference consortium}{18}{subsection.2.4.1}%
\contentsline {subsection}{\numberline {2.4.2}USCS genome browser}{18}{subsection.2.4.2}%
\contentsline {chapter}{\numberline {3}Genetic Fingerprinting}{19}{chapter.3}%
\contentsline {section}{\numberline {3.1}Introduction}{19}{section.3.1}%
\contentsline {subsection}{\numberline {3.1.1}Fields of interest}{19}{subsection.3.1.1}%
\contentsline {subsection}{\numberline {3.1.2}Variants used for genetic testing}{19}{subsection.3.1.2}%
\contentsline {subsubsection}{\numberline {3.1.2.1}CNVs}{19}{subsubsection.3.1.2.1}%
\contentsline {subsubsection}{\numberline {3.1.2.2}SNPs}{20}{subsubsection.3.1.2.2}%
\contentsline {section}{\numberline {3.2}SNPs features}{20}{section.3.2}%
\contentsline {subsection}{\numberline {3.2.1}Hardy-Weinberg equilibrium}{20}{subsection.3.2.1}%
\contentsline {subsection}{\numberline {3.2.2}Minor allele frequency}{20}{subsection.3.2.2}%
\contentsline {subsubsection}{\numberline {3.2.2.1}Optimal MAF values for genetic fingerprinting}{20}{subsubsection.3.2.2.1}%
\contentsline {subsection}{\numberline {3.2.3}Haplotype blocks}{21}{subsection.3.2.3}%
\contentsline {subsubsection}{\numberline {3.2.3.1}Linkage disequilibrium}{21}{subsubsection.3.2.3.1}%
\contentsline {subsubsection}{\numberline {3.2.3.2}Tag SNPs}{21}{subsubsection.3.2.3.2}%
\contentsline {subsection}{\numberline {3.2.4}Other SNP features}{22}{subsection.3.2.4}%
\contentsline {subsection}{\numberline {3.2.5}Number of SNPs to select when performing a genetic test}{22}{subsection.3.2.5}%
\contentsline {subsubsection}{\numberline {3.2.5.1}Experimental mismatches - Genotype call error rate}{22}{subsubsection.3.2.5.1}%
\contentsline {paragraph}{\numberline {3.2.5.1.1}An example on the effect of experimental mismatches}{23}{figure.caption.12}%
\contentsline {subsubsection}{\numberline {3.2.5.2}Biological mismatches}{23}{subsubsection.3.2.5.2}%
\contentsline {paragraph}{\numberline {3.2.5.2.1}Loss of Heterozygosity (LOH)}{23}{paragraph.3.2.5.2.1}%
\contentsline {paragraph}{\numberline {3.2.5.2.2}Gain Of Heterozygosity (GOH)}{23}{paragraph.3.2.5.2.2}%
\contentsline {paragraph}{\numberline {3.2.5.2.3}Double Mutation (DM)}{23}{paragraph.3.2.5.2.3}%
\contentsline {paragraph}{\numberline {3.2.5.2.4}Modelling biological mismatches}{23}{paragraph.3.2.5.2.4}%
\contentsline {subsection}{\numberline {3.2.6}Project regarding SNPs}{24}{subsection.3.2.6}%
\contentsline {subsubsection}{\numberline {3.2.6.1}dbSNPs}{24}{subsubsection.3.2.6.1}%
\contentsline {subsubsection}{\numberline {3.2.6.2}HapMap3}{24}{subsubsection.3.2.6.2}%
\contentsline {section}{\numberline {3.3}Genetic distance}{24}{section.3.3}%
\contentsline {subsection}{\numberline {3.3.1}Measuring distance}{24}{subsection.3.3.1}%
\contentsline {subsubsection}{\numberline {3.3.1.1}Expected distance}{26}{subsubsection.3.3.1.1}%
\contentsline {subsubsection}{\numberline {3.3.1.2}Identifying a sample origin from RAP samples}{27}{subsubsection.3.3.1.2}%
\contentsline {subsection}{\numberline {3.3.2}Distance changes with different numbers of SNPs}{28}{subsection.3.3.2}%
\contentsline {section}{\numberline {3.4}Building a SNP-based genetic test}{28}{section.3.4}%
\contentsline {subsection}{\numberline {3.4.1}Pipeline}{28}{subsection.3.4.1}%
\contentsline {subsection}{\numberline {3.4.2}Implementation of a probabilistic test to identify samples}{29}{subsection.3.4.2}%
\contentsline {subsubsection}{\numberline {3.4.2.1}Classification}{29}{subsubsection.3.4.2.1}%
\contentsline {subsection}{\numberline {3.4.3}Some examples of genetic tests}{30}{subsection.3.4.3}%
\contentsline {subsubsection}{\numberline {3.4.3.1}Investigating cell line passages}{30}{subsubsection.3.4.3.1}%
\contentsline {subsubsection}{\numberline {3.4.3.2}Investigating individual relatedness}{30}{subsubsection.3.4.3.2}%
\contentsline {subsection}{\numberline {3.4.4}Genetic structure of the human population}{31}{subsection.3.4.4}%
\contentsline {subsubsection}{\numberline {3.4.4.1}Genes mirror geography in Europe}{32}{subsubsection.3.4.4.1}%
\contentsline {chapter}{\numberline {4}IGV (Integrative Genomics Viewer)}{34}{chapter.4}%
\contentsline {section}{\numberline {4.1}IGV characteristics}{34}{section.4.1}%
\contentsline {subsection}{\numberline {4.1.1}Introduction}{34}{subsection.4.1.1}%
\contentsline {subsection}{\numberline {4.1.2}Main uses of IGV}{34}{subsection.4.1.2}%
\contentsline {subsubsection}{\numberline {4.1.2.1}RNA sequence analysis}{35}{subsubsection.4.1.2.1}%
\contentsline {subsubsection}{\numberline {4.1.2.2}Variant discovery}{36}{subsubsection.4.1.2.2}%
\contentsline {subsection}{\numberline {4.1.3}Operations}{36}{subsection.4.1.3}%
\contentsline {subsection}{\numberline {4.1.4}Tiles}{37}{subsection.4.1.4}%
\contentsline {subsubsection}{\numberline {4.1.4.1}Pixel resolution error}{37}{subsubsection.4.1.4.1}%
\contentsline {subsubsection}{\numberline {4.1.4.2}Data displayed at different resolutions}{38}{subsubsection.4.1.4.2}%
\contentsline {subsection}{\numberline {4.1.5}IGVTools}{38}{subsection.4.1.5}%
\contentsline {subsection}{\numberline {4.1.6}Session files}{38}{subsection.4.1.6}%
\contentsline {section}{\numberline {4.2}Interpreting pair orientations}{39}{section.4.2}%
\contentsline {subsection}{\numberline {4.2.1}Element to consider when interpreting pair orientations}{39}{subsection.4.2.1}%
\contentsline {subsection}{\numberline {4.2.2}Inversion}{39}{subsection.4.2.2}%
\contentsline {subsection}{\numberline {4.2.3}Tandem duplication}{40}{subsection.4.2.3}%
\contentsline {subsection}{\numberline {4.2.4}Inverted duplication}{40}{subsection.4.2.4}%
\contentsline {subsection}{\numberline {4.2.5}Deletion}{41}{subsection.4.2.5}%
\contentsline {section}{\numberline {4.3}Uncovering genetic aberrations - some examples}{41}{section.4.3}%
\contentsline {subsection}{\numberline {4.3.1}First example}{41}{subsection.4.3.1}%
\contentsline {subsection}{\numberline {4.3.2}Second example}{41}{subsection.4.3.2}%
\contentsline {subsection}{\numberline {4.3.3}Third example}{42}{subsection.4.3.3}%
\contentsline {chapter}{\numberline {5}Tumor Evolution Studies via NGS data}{44}{chapter.5}%
\contentsline {section}{\numberline {5.1}Tumour evolution}{44}{section.5.1}%
\contentsline {subsection}{\numberline {5.1.1}Introduction}{44}{subsection.5.1.1}%
\contentsline {subsubsection}{\numberline {5.1.1.1}Typical traits of cancer}{44}{subsubsection.5.1.1.1}%
\contentsline {subsubsection}{\numberline {5.1.1.2}Tumour boards}{44}{subsubsection.5.1.1.2}%
\contentsline {subsection}{\numberline {5.1.2}Heterogeneity}{45}{subsection.5.1.2}%
\contentsline {subsubsection}{\numberline {5.1.2.1}Temporal heterogeneity}{45}{subsubsection.5.1.2.1}%
\contentsline {subsubsection}{\numberline {5.1.2.2}Spatial heterogeneity}{45}{subsubsection.5.1.2.2}%
\contentsline {subsection}{\numberline {5.1.3}Type of evolutions}{45}{subsection.5.1.3}%
\contentsline {subsubsection}{\numberline {5.1.3.1}Linear evolution}{46}{subsubsection.5.1.3.1}%
\contentsline {subsubsection}{\numberline {5.1.3.2}Branched evolution}{46}{subsubsection.5.1.3.2}%
\contentsline {subsection}{\numberline {5.1.4}Treatment resistance}{46}{subsection.5.1.4}%
\contentsline {subsubsection}{\numberline {5.1.4.1}Primary resistance}{47}{subsubsection.5.1.4.1}%
\contentsline {subsubsection}{\numberline {5.1.4.2}Acquired resistance}{47}{subsubsection.5.1.4.2}%
\contentsline {section}{\numberline {5.2}Using NGS data to uncover tumour evolution}{47}{section.5.2}%
\contentsline {subsection}{\numberline {5.2.1}Introduction}{47}{subsection.5.2.1}%
\contentsline {subsection}{\numberline {5.2.2}Admixture}{48}{subsection.5.2.2}%
\contentsline {subsection}{\numberline {5.2.3}Informative SNPs}{48}{subsection.5.2.3}%
\contentsline {subsection}{\numberline {5.2.4}Beta value}{49}{subsection.5.2.4}%
\contentsline {subsubsection}{\numberline {5.2.4.1}Computing beta}{50}{subsubsection.5.2.4.1}%
\contentsline {subsubsection}{\numberline {5.2.4.2}Effect of coverage on beta}{51}{subsubsection.5.2.4.2}%
\contentsline {subsection}{\numberline {5.2.5}Estimates of global and local admixture}{51}{subsection.5.2.5}%
\contentsline {subsubsection}{\numberline {5.2.5.1}Estimates of DNA admixture}{52}{subsubsection.5.2.5.1}%
\contentsline {subsection}{\numberline {5.2.6}PR-2741 - an example}{53}{subsection.5.2.6}%
\contentsline {chapter}{\numberline {6}Tumor evolution studies: copy number based methods}{55}{chapter.6}%
\contentsline {section}{\numberline {6.1}Analysis of clonality}{55}{section.6.1}%
\contentsline {subsection}{\numberline {6.1.1}Informative SNPs}{55}{subsection.6.1.1}%
\contentsline {subsection}{\numberline {6.1.2}Log2 ratio}{55}{subsection.6.1.2}%
\contentsline {subsection}{\numberline {6.1.3}Beta value}{56}{subsection.6.1.3}%
\contentsline {subsection}{\numberline {6.1.4}Cluster analysis in the beta-log2 ratio space}{56}{subsection.6.1.4}%
\contentsline {section}{\numberline {6.2}Evolution maps}{57}{section.6.2}%
\contentsline {subsection}{\numberline {6.2.1}Introduction}{57}{subsection.6.2.1}%
\contentsline {subsection}{\numberline {6.2.2}Building an evolution map}{57}{subsection.6.2.2}%
\contentsline {subsection}{\numberline {6.2.3}A toy example}{57}{subsection.6.2.3}%
\contentsline {subsection}{\numberline {6.2.4}A real world data example}{59}{subsection.6.2.4}%
\contentsline {subsubsection}{\numberline {6.2.4.1}Limitations}{59}{subsubsection.6.2.4.1}%
\contentsline {subsection}{\numberline {6.2.5}Pathway-based evolutionary maps}{59}{subsection.6.2.5}%
\contentsline {subsubsection}{\numberline {6.2.5.1}Timing}{60}{subsubsection.6.2.5.1}%
\contentsline {subsubsection}{\numberline {6.2.5.2}Treatment}{60}{subsubsection.6.2.5.2}%
\contentsline {section}{\numberline {6.3}Ploidy and purity corrections}{60}{section.6.3}%
\contentsline {subsection}{\numberline {6.3.1}Introduction}{60}{subsection.6.3.1}%
\contentsline {subsection}{\numberline {6.3.2}A melanoma example}{61}{subsection.6.3.2}%
\contentsline {subsubsection}{\numberline {6.3.2.1}Ploidy correction}{61}{subsubsection.6.3.2.1}%
\contentsline {subsubsection}{\numberline {6.3.2.2}Purity correction}{62}{subsubsection.6.3.2.2}%
\contentsline {subsection}{\numberline {6.3.3}A melanoma example considering more samples}{62}{subsection.6.3.3}%
\contentsline {subsection}{\numberline {6.3.4}An example with TGCA data}{63}{subsection.6.3.4}%
\contentsline {subsubsection}{\numberline {6.3.4.1}Ploidy correction}{63}{subsubsection.6.3.4.1}%
\contentsline {section}{\numberline {6.4}Allele-specific analysis}{64}{section.6.4}%
\contentsline {subsection}{\numberline {6.4.1}Introduction}{64}{subsection.6.4.1}%
\contentsline {subsection}{\numberline {6.4.2}An example}{65}{subsection.6.4.2}%
\contentsline {subsubsection}{\numberline {6.4.2.1}Changes of copy number for specific alleles}{66}{subsubsection.6.4.2.1}%
\contentsline {subsubsection}{\numberline {6.4.2.2}Copy number neutral events}{66}{subsubsection.6.4.2.2}%
\contentsline {subsection}{\numberline {6.4.3}A case study}{67}{subsection.6.4.3}%
\contentsline {subsubsection}{\numberline {6.4.3.1}Primary site}{68}{subsubsection.6.4.3.1}%
\contentsline {subsubsection}{\numberline {6.4.3.2}Metastasis}{68}{subsubsection.6.4.3.2}%
\contentsline {section}{\numberline {6.5}Longitudinal plasma profiling}{69}{section.6.5}%
\contentsline {subsection}{\numberline {6.5.1}An example}{69}{subsection.6.5.1}%
\contentsline {subsection}{\numberline {6.5.2}Tracking evolution}{70}{subsection.6.5.2}%
\contentsline {chapter}{\numberline {7}Tumor evolution studies: SNVs-based methods}{71}{chapter.7}%
\contentsline {section}{\numberline {7.1}Introduction}{71}{section.7.1}%
\contentsline {subsection}{\numberline {7.1.1}Copy-number neutral tumours}{71}{subsection.7.1.1}%
\contentsline {subsection}{\numberline {7.1.2}Different methods for tumour assessment}{72}{subsection.7.1.2}%
\contentsline {subsection}{\numberline {7.1.3}Rationale of SNV based methods}{72}{subsection.7.1.3}%
\contentsline {subsection}{\numberline {7.1.4}Advantages and limitations of SNVs based methods}{72}{subsection.7.1.4}%
\contentsline {subsection}{\numberline {7.1.5}Reference mapping bias}{73}{subsection.7.1.5}%
\contentsline {section}{\numberline {7.2}TPES - tumour purity estimation from SNVs}{73}{section.7.2}%
\contentsline {subsection}{\numberline {7.2.1}Introduction}{73}{subsection.7.2.1}%
\contentsline {subsection}{\numberline {7.2.2}SNV identification}{73}{subsection.7.2.2}%
\contentsline {subsubsection}{\numberline {7.2.2.1}Selection of copy-number neutral segments}{74}{subsubsection.7.2.2.1}%
\contentsline {subsubsection}{\numberline {7.2.2.2}Allelic fraction}{74}{subsubsection.7.2.2.2}%
\contentsline {subsubsection}{\numberline {7.2.2.3}Identification of putative clonal SNVs}{74}{subsubsection.7.2.2.3}%
\contentsline {subsection}{\numberline {7.2.3}Purity estimation}{74}{subsection.7.2.3}%
\contentsline {subsection}{\numberline {7.2.4}Minimal number of SNV for tumour identification}{74}{subsection.7.2.4}%
\contentsline {subsection}{\numberline {7.2.5}Comparison with other tumour callers}{75}{subsection.7.2.5}%
\contentsline {chapter}{\numberline {8}Liquid biopsies in oncology}{76}{chapter.8}%
\contentsline {section}{\numberline {8.1}Introduction}{76}{section.8.1}%
\contentsline {subsection}{\numberline {8.1.1}Tracking tumour progression}{76}{subsection.8.1.1}%
\contentsline {subsection}{\numberline {8.1.2}Differences between tissue and liquid biopsies}{76}{subsection.8.1.2}%
\contentsline {subsubsection}{\numberline {8.1.2.1}Liquid biopsies allow to perform a number of analysis}{77}{subsubsection.8.1.2.1}%
\contentsline {subsubsection}{\numberline {8.1.2.2}Material availability}{77}{subsubsection.8.1.2.2}%
\contentsline {subsubsection}{\numberline {8.1.2.3}Tumour content}{77}{subsubsection.8.1.2.3}%
\contentsline {subsubsection}{\numberline {8.1.2.4}Assessment of tumour ploidy}{77}{subsubsection.8.1.2.4}%
\contentsline {subsection}{\numberline {8.1.3}Application-dependent requirements}{78}{subsection.8.1.3}%
\contentsline {subsubsection}{\numberline {8.1.3.1}Early tumour, MRD and recurrence detection}{78}{subsubsection.8.1.3.1}%
\contentsline {subsubsection}{\numberline {8.1.3.2}Analysis of tumour dynamics, treatment response and analysis of the mechanisms of resistance}{78}{subsubsection.8.1.3.2}%
\contentsline {subsubsection}{\numberline {8.1.3.3}Single biomarker assessment}{78}{subsubsection.8.1.3.3}%
\contentsline {subsection}{\numberline {8.1.4}Whole-genome and targeted sequencing}{78}{subsection.8.1.4}%
\contentsline {subsection}{\numberline {8.1.5}Challenges in tracking tumour evolution with liquid biopsies}{79}{subsection.8.1.5}%
\contentsline {subsubsection}{\numberline {8.1.5.1}An example of similarity between two plasma samples between two different tumours}{79}{subsubsection.8.1.5.1}%
\contentsline {section}{\numberline {8.2}Interpretation of cell free DNA data}{79}{section.8.2}%
\contentsline {subsection}{\numberline {8.2.1}Introduction}{79}{subsection.8.2.1}%
\contentsline {subsection}{\numberline {8.2.2}Normalization}{79}{subsection.8.2.2}%
\contentsline {subsection}{\numberline {8.2.3}Quantity of input material}{80}{subsection.8.2.3}%
\contentsline {subsection}{\numberline {8.2.4}SNVs detection}{81}{subsection.8.2.4}%
\contentsline {subsubsection}{\numberline {8.2.4.1}Technical problems}{81}{subsubsection.8.2.4.1}%
\contentsline {subsubsection}{\numberline {8.2.4.2}Biological problems}{82}{subsubsection.8.2.4.2}%
\contentsline {subsection}{\numberline {8.2.5}Two case studies}{82}{subsection.8.2.5}%
\contentsline {subsubsection}{\numberline {8.2.5.1}Signal distribution in prostate cancer}{82}{subsubsection.8.2.5.1}%
\contentsline {subsubsection}{\numberline {8.2.5.2}Non-AR driven castration resistance prostate cancer}{82}{subsubsection.8.2.5.2}%
\contentsline {chapter}{\numberline {9}Extracellular vesicles}{84}{chapter.9}%
\contentsline {section}{\numberline {9.1}Introduction}{84}{section.9.1}%
\contentsline {subsection}{\numberline {9.1.1}Definition}{84}{subsection.9.1.1}%
\contentsline {subsection}{\numberline {9.1.2}Compartments of extracellular vesicles}{84}{subsection.9.1.2}%
\contentsline {subsubsection}{\numberline {9.1.2.1}Outside layer}{84}{subsubsection.9.1.2.1}%
\contentsline {subsubsection}{\numberline {9.1.2.2}Content}{84}{subsubsection.9.1.2.2}%
\contentsline {subsubsection}{\numberline {9.1.2.3}Membrane proteins}{85}{subsubsection.9.1.2.3}%
\contentsline {subsection}{\numberline {9.1.3}Characterization of extracellular vesicles}{85}{subsection.9.1.3}%
\contentsline {subsubsection}{\numberline {9.1.3.1}Size}{85}{subsubsection.9.1.3.1}%
\contentsline {subsubsection}{\numberline {9.1.3.2}Origin}{85}{subsubsection.9.1.3.2}%
\contentsline {paragraph}{\numberline {9.1.3.2.1}Process of origin of exosomes}{85}{paragraph.9.1.3.2.1}%
\contentsline {subsubsection}{\numberline {9.1.3.3}Content}{86}{subsubsection.9.1.3.3}%
\contentsline {paragraph}{\numberline {9.1.3.3.1}Exosomes and microvesicles}{86}{paragraph.9.1.3.3.1}%
\contentsline {paragraph}{\numberline {9.1.3.3.2}Apoptotic bodies}{86}{paragraph.9.1.3.3.2}%
\contentsline {paragraph}{\numberline {9.1.3.3.3}Exosomes}{86}{paragraph.9.1.3.3.3}%
\contentsline {subsection}{\numberline {9.1.4}Functions of extracellular vesicles}{87}{subsection.9.1.4}%
\contentsline {subsubsection}{\numberline {9.1.4.1}Functions of extracellular vesicles in cancer}{87}{subsubsection.9.1.4.1}%
\contentsline {section}{\numberline {9.2}Tumour studies through extracellular vesicles analysis}{87}{section.9.2}%
\contentsline {subsection}{\numberline {9.2.1}Introduction}{87}{subsection.9.2.1}%
\contentsline {subsection}{\numberline {9.2.2}Breast cancer - an example}{88}{subsection.9.2.2}%
\contentsline {subsection}{\numberline {9.2.3}Tracking tumour signal in serial samples}{88}{subsection.9.2.3}%
\contentsline {subsection}{\numberline {9.2.4}Extracellular vesicles isolation methods}{88}{subsection.9.2.4}%
\contentsline {subsection}{\numberline {9.2.5}Challenges in studying tumour evolution through extracellular vesicles}{89}{subsection.9.2.5}%
\contentsline {subsection}{\numberline {9.2.6}Deconvolution}{89}{subsection.9.2.6}%
\contentsline {subsubsection}{\numberline {9.2.6.1}Supervised deconvolution}{89}{subsubsection.9.2.6.1}%
\contentsline {subsubsection}{\numberline {9.2.6.2}Unsupervised deconvolution}{90}{subsubsection.9.2.6.2}%
\contentsline {subsection}{\numberline {9.2.7}Conclusion}{90}{subsection.9.2.7}%
\contentsline {chapter}{\numberline {10}Epigenetic profiling of cell-free DNA}{91}{chapter.10}%
\contentsline {section}{\numberline {10.1}Introduction}{91}{section.10.1}%
\contentsline {subsection}{\numberline {10.1.1}Epigenetic}{91}{subsection.10.1.1}%
\contentsline {subsubsection}{\numberline {10.1.1.1}Epigenetic modifications}{91}{subsubsection.10.1.1.1}%
\contentsline {subsubsection}{\numberline {10.1.1.2}Epigenetic plasticity}{91}{subsubsection.10.1.1.2}%
\contentsline {subsubsection}{\numberline {10.1.1.3}Epigenetic deregulation}{91}{subsubsection.10.1.1.3}%
\contentsline {subsection}{\numberline {10.1.2}DNA methylation}{91}{subsection.10.1.2}%
\contentsline {subsubsection}{\numberline {10.1.2.1}CpG islands}{92}{subsubsection.10.1.2.1}%
\contentsline {subsubsection}{\numberline {10.1.2.2}Cancer tissues}{92}{subsubsection.10.1.2.2}%
\contentsline {subsubsection}{\numberline {10.1.2.3}Landscape of regulation}{92}{subsubsection.10.1.2.3}%
\contentsline {subsubsection}{\numberline {10.1.2.4}DNA methylation markers}{93}{subsubsection.10.1.2.4}%
\contentsline {subsection}{\numberline {10.1.3}Measuring DNA methylation}{93}{subsection.10.1.3}%
\contentsline {subsubsection}{\numberline {10.1.3.1}Bisulphite conversion}{93}{subsubsection.10.1.3.1}%
\contentsline {subsubsection}{\numberline {10.1.3.2}Sequencing and alignment}{93}{subsubsection.10.1.3.2}%
\contentsline {subsubsection}{\numberline {10.1.3.3}Computing beta values}{93}{subsubsection.10.1.3.3}%
\contentsline {subsubsection}{\numberline {10.1.3.4}Single read analysis}{94}{subsubsection.10.1.3.4}%
\contentsline {section}{\numberline {10.2}DNA methylation based liquid biopsy}{94}{section.10.2}%
\contentsline {subsection}{\numberline {10.2.1}Introduction}{94}{subsection.10.2.1}%
\contentsline {subsection}{\numberline {10.2.2}Comparison with genomics-based liquid biopsies}{94}{subsection.10.2.2}%
\contentsline {subsection}{\numberline {10.2.3}Workflow}{95}{subsection.10.2.3}%
\contentsline {subsection}{\numberline {10.2.4}CCGA study}{95}{subsection.10.2.4}%
\contentsline {subsubsection}{\numberline {10.2.4.1}Obtaining methylation profiles}{95}{subsubsection.10.2.4.1}%
\contentsline {subsubsection}{\numberline {10.2.4.2}Results}{96}{subsubsection.10.2.4.2}%
\contentsline {subsection}{\numberline {10.2.5}Deconvolution approach}{96}{subsection.10.2.5}%
\contentsline {subsubsection}{\numberline {10.2.5.1}Considering liquid biopsies}{96}{subsubsection.10.2.5.1}%
\contentsline {subsubsection}{\numberline {10.2.5.2}High-quality reference atlases}{96}{subsubsection.10.2.5.2}%
\contentsline {subsection}{\numberline {10.2.6}Targeted panel approaches for tumour content estimation}{96}{subsection.10.2.6}%
\contentsline {part}{II\hspace {1em}Laboratory}{97}{part.2}%
\contentsline {chapter}{\numberline {11}Relevant file's formats}{98}{chapter.11}%
\contentsline {section}{\numberline {11.1}FASTA format}{98}{section.11.1}%
\contentsline {subsection}{\numberline {11.1.1}Components}{98}{subsection.11.1.1}%
\contentsline {subsection}{\numberline {11.1.2}Alphabet}{98}{subsection.11.1.2}%
\contentsline {subsection}{\numberline {11.1.3}DNA sequence quality}{98}{subsection.11.1.3}%
\contentsline {section}{\numberline {11.2}FASTQ format}{99}{section.11.2}%
\contentsline {subsection}{\numberline {11.2.1}Data compression}{99}{subsection.11.2.1}%
\contentsline {section}{\numberline {11.3}SAM and BAM formats}{99}{section.11.3}%
\contentsline {subsection}{\numberline {11.3.1}SAM files}{99}{subsection.11.3.1}%
\contentsline {subsubsection}{\numberline {11.3.1.1}COmposition}{99}{subsubsection.11.3.1.1}%
\contentsline {subsection}{\numberline {11.3.2}BAM files}{99}{subsection.11.3.2}%
\contentsline {subsection}{\numberline {11.3.3}Operation with SAM and BAM files}{99}{subsection.11.3.3}%
\contentsline {subsubsection}{\numberline {11.3.3.1}Converting from SAM to BAM}{100}{subsubsection.11.3.3.1}%
\contentsline {subsubsection}{\numberline {11.3.3.2}Filtering}{100}{subsubsection.11.3.3.2}%
\contentsline {subsubsection}{\numberline {11.3.3.3}Explore statistics}{100}{subsubsection.11.3.3.3}%
\contentsline {subsubsection}{\numberline {11.3.3.4}Mpileup}{100}{subsubsection.11.3.3.4}%
\contentsline {chapter}{\numberline {12}Data pre-processing}{101}{chapter.12}%
\contentsline {section}{\numberline {12.1}Realignment}{101}{section.12.1}%
\contentsline {subsection}{\numberline {12.1.1}Introduction}{101}{subsection.12.1.1}%
\contentsline {subsection}{\numberline {12.1.2}An example}{101}{subsection.12.1.2}%
\contentsline {subsection}{\numberline {12.1.3}Objective of realignment}{101}{subsection.12.1.3}%
\contentsline {subsection}{\numberline {12.1.4}GATK}{101}{subsection.12.1.4}%
\contentsline {subsection}{\numberline {12.1.5}Protocol}{102}{subsection.12.1.5}%
\contentsline {subsection}{\numberline {12.1.6}Realignment results}{102}{subsection.12.1.6}%
\contentsline {section}{\numberline {12.2}Recalibration}{102}{section.12.2}%
\contentsline {subsection}{\numberline {12.2.1}Introduction}{102}{subsection.12.2.1}%
\contentsline {subsubsection}{\numberline {12.2.1.1}Dealing with systematic errors}{102}{subsubsection.12.2.1.1}%
\contentsline {subsection}{\numberline {12.2.2}Computing empirical qualities}{102}{subsection.12.2.2}%
\contentsline {subsubsection}{\numberline {12.2.2.1}Base quality score recalibration}{103}{subsubsection.12.2.2.1}%
\contentsline {subsection}{\numberline {12.2.3}Protocol}{103}{subsection.12.2.3}%
\contentsline {section}{\numberline {12.3}Marking duplicates}{103}{section.12.3}%
\contentsline {subsection}{\numberline {12.3.1}Introduction}{103}{subsection.12.3.1}%
\contentsline {subsection}{\numberline {12.3.2}Identification of duplicates}{103}{subsection.12.3.2}%
\contentsline {subsubsection}{\numberline {12.3.2.1}Consideration on Borrow-Wheeler aligner}{104}{subsubsection.12.3.2.1}%
\contentsline {subsection}{\numberline {12.3.3}Protocol}{104}{subsection.12.3.3}%
\contentsline {chapter}{\numberline {13}Variant calling}{105}{chapter.13}%
\contentsline {chapter}{\numberline {14}Variant annotation}{106}{chapter.14}%
\contentsline {chapter}{\numberline {15}Ancestry}{107}{chapter.15}%
\contentsline {chapter}{\numberline {16}Somatic variant calling}{108}{chapter.16}%
\contentsline {chapter}{\numberline {17}Somatic copy number calling}{109}{chapter.17}%
\contentsline {part}{III\hspace {1em}Papers}{110}{part.3}%
\contentsline {chapter}{\numberline {18}Role of non-coding sequence variants in cancer}{111}{chapter.18}%
\contentsline {section}{\numberline {18.1}Abstract}{111}{section.18.1}%
\contentsline {subsection}{\numberline {18.1.1}Introduction}{111}{subsection.18.1.1}%
\contentsline {section}{\numberline {18.2}Genomic sequence variants}{111}{section.18.2}%
\contentsline {section}{\numberline {18.3}Non-coding element annotation}{112}{section.18.3}%
\contentsline {subsection}{\numberline {18.3.1}Cis regulatory regions}{112}{subsection.18.3.1}%
\contentsline {subsection}{\numberline {18.3.2}Distal regulatory elements}{112}{subsection.18.3.2}%
\contentsline {subsection}{\numberline {18.3.3}RNA-seq}{112}{subsection.18.3.3}%
\contentsline {subsection}{\numberline {18.3.4}Transcribed pseudogenes}{112}{subsection.18.3.4}%
\contentsline {subsection}{\numberline {18.3.5}Evolutionary conservation}{113}{subsection.18.3.5}%
\contentsline {section}{\numberline {18.4}Roles for somatic variants in cancer}{113}{section.18.4}%
\contentsline {subsection}{\numberline {18.4.1}Gain of TF-binding sites}{113}{subsection.18.4.1}%
\contentsline {subsection}{\numberline {18.4.2}Fusion events due to genomic rearrangements}{113}{subsection.18.4.2}%
\contentsline {subsection}{\numberline {18.4.3}ncRNAs and their binding sites}{113}{subsection.18.4.3}%
\contentsline {subsection}{\numberline {18.4.4}Role of pseudogenes in modulating the expression of a parental gene}{114}{subsection.18.4.4}%
\contentsline {section}{\numberline {18.5}Roles for germline variants in cancer}{114}{section.18.5}%
\contentsline {subsection}{\numberline {18.5.1}Promoter mutations}{114}{subsection.18.5.1}%
\contentsline {subsection}{\numberline {18.5.2}SNPs in enhancers}{114}{subsection.18.5.2}%
\contentsline {subsection}{\numberline {18.5.3}Variants in introns}{114}{subsection.18.5.3}%
\contentsline {subsection}{\numberline {18.5.4}SNPs in ncRNA and their binding sites}{114}{subsection.18.5.4}%
\contentsline {subsection}{\numberline {18.5.5}Others}{114}{subsection.18.5.5}%
\contentsline {section}{\numberline {18.6}Interplay between germline and somatic variants}{114}{section.18.6}%
\contentsline {section}{\numberline {18.7}Computational methods for identifying variants}{115}{section.18.7}%
\contentsline {section}{\numberline {18.8}Experimental approaches for functional validation}{115}{section.18.8}%
\contentsline {chapter}{\numberline {19}Advances in understanding cancer genomics through second-generation sequencing}{117}{chapter.19}%
\contentsline {section}{\numberline {19.1}Abstract}{117}{section.19.1}%
\contentsline {subsection}{\numberline {19.1.1}Introduction}{117}{subsection.19.1.1}%
\contentsline {section}{\numberline {19.2}Cancer-specific consideration}{117}{section.19.2}%
\contentsline {subsection}{\numberline {19.2.1}Characteristics of cancer samples for genomic analysis}{118}{subsection.19.2.1}%
\contentsline {subsection}{\numberline {19.2.2}Structural variability of cancer genomes}{118}{subsection.19.2.2}%
\contentsline {section}{\numberline {19.3}Experimental approaches}{118}{section.19.3}%
\contentsline {subsection}{\numberline {19.3.1}Whole genome sequencing}{118}{subsection.19.3.1}%
\contentsline {subsection}{\numberline {19.3.2}Exome sequencing}{118}{subsection.19.3.2}%
\contentsline {subsection}{\numberline {19.3.3}Transcriptome sequencing}{119}{subsection.19.3.3}%
\contentsline {section}{\numberline {19.4}Detecting classes of genome alterations}{119}{section.19.4}%
\contentsline {subsection}{\numberline {19.4.1}Somatic nucleotide substitutions and small insertion and deletion mutations}{119}{subsection.19.4.1}%
\contentsline {subsection}{\numberline {19.4.2}Copy number}{119}{subsection.19.4.2}%
\contentsline {subsection}{\numberline {19.4.3}Chromosomal rearrangements}{119}{subsection.19.4.3}%
\contentsline {subsection}{\numberline {19.4.4}Microbe-discovery methods}{120}{subsection.19.4.4}%
\contentsline {section}{\numberline {19.5}Computational issues}{120}{section.19.5}%
\contentsline {subsection}{\numberline {19.5.1}Alignment and assembly}{120}{subsection.19.5.1}%
\contentsline {subsection}{\numberline {19.5.2}mutations detection}{120}{subsection.19.5.2}%
\contentsline {subsection}{\numberline {19.5.3}Validation of mutation and rearrangement calls}{120}{subsection.19.5.3}%
\contentsline {chapter}{\numberline {20}Integrative genomics viewer}{122}{chapter.20}%
\contentsline {section}{\numberline {20.1}Introduction}{122}{section.20.1}%
\contentsline {chapter}{\numberline {21}Tumour heterogeneity and resistance to cancer therapies}{123}{chapter.21}%
\contentsline {section}{\numberline {21.1}Abstract}{123}{section.21.1}%
\contentsline {subsection}{\numberline {21.1.1}Introduction}{123}{subsection.21.1.1}%
\contentsline {section}{\numberline {21.2}Causes of intratumoral heterogeneity}{123}{section.21.2}%
\contentsline {subsection}{\numberline {21.2.1}Genomic instability}{123}{subsection.21.2.1}%
\contentsline {subsection}{\numberline {21.2.2}The clonal evolution and selection hypothesis}{124}{subsection.21.2.2}%
\contentsline {section}{\numberline {21.3}The spectrum of tumour heterogeneity}{124}{section.21.3}%
\contentsline {subsection}{\numberline {21.3.1}Spatial heterogeneity}{124}{subsection.21.3.1}%
\contentsline {subsubsection}{\numberline {21.3.1.1}Heterogeneity at a single disease site}{124}{subsubsection.21.3.1.1}%
\contentsline {subsubsection}{\numberline {21.3.1.2}Comparison of spatially distinct disease sites}{124}{subsubsection.21.3.1.2}%
\contentsline {subsection}{\numberline {21.3.2}Temporal heterogeneity}{125}{subsection.21.3.2}%
\contentsline {subsubsection}{\numberline {21.3.2.1}Genomic complexity might increase with exposure to targeted therapies}{125}{subsubsection.21.3.2.1}%
\contentsline {subsubsection}{\numberline {21.3.2.2}Longitudinal sampling provides insight into temporal heterogeneity}{125}{subsubsection.21.3.2.2}%
\contentsline {subsubsection}{\numberline {21.3.2.3}Residual drug-tolerant cells can foster temporal heterogeneity}{125}{subsubsection.21.3.2.3}%
\contentsline {section}{\numberline {21.4}Noninvasive monitoring of heterogeneity}{126}{section.21.4}%
\contentsline {subsection}{\numberline {21.4.1}Analysis of ctDNA}{126}{subsection.21.4.1}%
\contentsline {section}{\numberline {21.5}Overcoming heterogeneity}{126}{section.21.5}%
\contentsline {chapter}{\numberline {22}Unravelling the clonal hierarchy of somatic genomic aberrations}{128}{chapter.22}%
\contentsline {section}{\numberline {22.1}Introduction}{128}{section.22.1}%
\contentsline {subsection}{\numberline {22.1.1}Abstract}{128}{subsection.22.1.1}%
\contentsline {subsection}{\numberline {22.1.2}Background}{128}{subsection.22.1.2}%
\contentsline {section}{\numberline {22.2}Results}{129}{section.22.2}%
\contentsline {subsection}{\numberline {22.2.1}Clonality assessment of aberrations from sequencing reads}{129}{subsection.22.2.1}%
\contentsline {subsection}{\numberline {22.2.2}Inferring the order of mutations in a tumour sample}{130}{subsection.22.2.2}%
\contentsline {subsection}{\numberline {22.2.3}In silico and in situ experimental validation}{130}{subsection.22.2.3}%
\contentsline {subsection}{\numberline {22.2.4}Comparative analysis reveals different mechanisms of tumour deregulation}{130}{subsection.22.2.4}%
\contentsline {subsection}{\numberline {22.2.5}Clonal hierarchy of genomic aberrations}{131}{subsection.22.2.5}%
\contentsline {section}{\numberline {22.3}Materials and methods}{131}{section.22.3}%
\contentsline {subsection}{\numberline {22.3.1}CLONET pipeline}{131}{subsection.22.3.1}%
\contentsline {subsection}{\numberline {22.3.2}CLONET on exome and targeted sequencing data}{131}{subsection.22.3.2}%
\contentsline {subsection}{\numberline {22.3.3}Expected distribution of the allelic fraction of a genomic segment}{131}{subsection.22.3.3}%
\contentsline {subsection}{\numberline {22.3.4}Estimated proportion of neutral reads for a genomic segment}{132}{subsection.22.3.4}%
\contentsline {subsection}{\numberline {22.3.5}From neutral to non-aberrant reads}{132}{subsection.22.3.5}%
\contentsline {subsection}{\numberline {22.3.6}From aberrant reads to aberrant cells}{132}{subsection.22.3.6}%
\contentsline {subsection}{\numberline {22.3.7}Uncertainty assessment and its propagation to clonality estimates}{133}{subsection.22.3.7}%
\contentsline {subsection}{\numberline {22.3.8}Clonality of bi-allelic deletion}{133}{subsection.22.3.8}%
\contentsline {chapter}{\numberline {23}TPES: timor purity estimation from SNVs}{134}{chapter.23}%
\contentsline {section}{\numberline {23.1}Abstract}{134}{section.23.1}%
\contentsline {subsection}{\numberline {23.1.1}Introduction}{134}{subsection.23.1.1}%
\contentsline {section}{\numberline {23.2}Materials and methods}{134}{section.23.2}%
\contentsline {chapter}{\numberline {24}SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines}{136}{chapter.24}%
\contentsline {section}{\numberline {24.1}Abstract}{136}{section.24.1}%
\contentsline {subsection}{\numberline {24.1.1}Introduction}{136}{subsection.24.1.1}%
\contentsline {section}{\numberline {24.2}Material and methods}{136}{section.24.2}%
\contentsline {subsection}{\numberline {24.2.1}Genotype distance}{136}{subsection.24.2.1}%
\contentsline {subsection}{\numberline {24.2.2}SNP panel selection procedure}{137}{subsection.24.2.2}%
\contentsline {subsection}{\numberline {24.2.3}SPIA probabilistic test on cell line genotype distance}{137}{subsection.24.2.3}%
